Mirum Pharmaceuticals Expands Workforce to Enhance Rare Disease Treatment Development

Mirum Pharmaceuticals Enhances Talent Pool to Drive Rare Disease Treatment Initiatives

Mirum Pharmaceuticals, Inc. strengthens its workforce by granting inducement awards to eight new employees, a move that highlights the company’s strategic commitment to developing therapies for rare diseases. Announced on January 10, 2025, the awards comprise non-qualified stock options for 53,900 shares and 26,950 restricted stock units (RSUs) under the 2020 Inducement Plan. The stock options are set at an exercise price of $41.32, reflecting Mirum's closing share price on the grant date. Vested over four years, the options will see 25% vesting after the first year, followed by monthly vesting for the remaining three years, contingent on the employees’ continued service. Similarly, the RSUs will vest over three years, with one-third vesting on each anniversary.

This strategic inducement is crucial as Mirum Pharmaceuticals aims to bolster its capabilities in the highly specialized field of rare disease treatment. The company currently markets three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid), and CHENODAL® (chenodiol). LIVMARLI, an IBAT inhibitor, is specifically designed to alleviate cholestatic pruritus in patients suffering from Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). Ongoing studies are in place to explore potential label expansions, enhancing treatment options for patients with rare liver diseases. Meanwhile, CHOLBAM and CHENODAL address bile acid synthesis disorders and cerebrotendinous xanthomatosis (CTX), respectively, solidifying Mirum's position as a leader in rare disease therapeutics.

Furthermore, Mirum Pharmaceuticals is actively advancing its late-stage pipeline with investigational treatments, such as Volixibat, which is currently evaluated in two Phase 2 registrational studies, including the VISTAS study. This focus on innovative research aligns with the company's mission to transform the landscape of rare disease treatment for both children and adults. The recent inducement awards not only reflect Mirum's commitment to attracting top talent but also serve as a catalyst for furthering its product development initiatives in a challenging and competitive biopharmaceutical environment.

In addition to its core mission, the inducement awards underscore the company’s alignment with Nasdaq Listing Rule 5635(c)(4), ensuring compliance while fostering a robust workforce. Mirum Pharmaceuticals is well-positioned to leverage this new talent as it navigates the complexities of rare disease treatment and strives for continued growth and innovation in the biopharmaceutical sector.